Biotech
-
Will the first approved psychedelic become a blockbuster?
Compass and Usona are vying for an FDA first, but pricing, payer coverage and patient access could determine the commercial winner.
By Meagan Parrish • Nov. 20, 2026 -
Erasca data add to pressure facing Revolution’s breakthrough cancer drug
Rasonque is already off to one of the best oncology launches in history. But certain limitations leave an opportunity that companies like Erasca — which is nearing the start of a Phase 3 trial — may be able to exploit.
By Jonathan Gardner • Nov. 20, 2026 -
Explore the Trendline➔
Spencer Platt via Getty Images
TrendlineEmerging biotech
New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.
By BioPharma Dive staff -
News roundup
Celldex drug stumbles in eczema; Epigenetic editing startup cuts staff
Wall Street analysts rushed to Celldex’s defense following the setback. Elsewhere, Isomorphic Labs cut a cancer-focused deal with Merck and Teva’s research chief accepted a new job.
By Ben Fidler • Nov. 20, 2026 -
This week in charts
This week in charts: Biotech investors’ China bets are already paying off
This year, companies built around medicines from China have sped toward acquisitions or IPOs. Meanwhile, Summit is no longer the Wall Street darling it was in 2024.
By Ben Fidler • Nov. 20, 2026 -
China competition
China could ‘corner’ biopharma sector with new plan, US panel warns
A commission called on U.S. lawmakers to act quickly to prevent an “overdependence” on China that could leave American patients “vulnerable to supply chain weaponization.”
By Jonathan Gardner • Nov. 19, 2026 -
With FDA nod, Regeneron brings an RNAi drug to autoimmune disease
The product of a collaboration with Alnylam, Livsayis is now Regeneron’s first marketed RNAi drug and will compete against established medicines from AstraZeneca and Argenx.
By Ben Fidler • Nov. 19, 2026 -
News roundup
FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK
The FDA had several issues with ivonescimab, according to the letter. Elsewhere, Sellas shares rocketed on results for a leukemia vaccine and Biogen and Lilly struck up new R&D pacts.
By BioPharma Dive staff • Nov. 18, 2026 -
Emerging biotech
AI drugmaker Isomorphic restocks with $5B fundraise
Even as the larger AI industry faces turmoil, investors have given Isomorphic the two largest cash infusions in the biotech sector this year.
By Kristin Jensen • Nov. 17, 2026 -
Startup launches
Marrow sets out to challenge genetic medicines for severe blood diseases
Armed with $173 million in venture funding, the startup is developing what it’s positioning as a more accessible alternative to gene therapy and gene editing treatments for sickle cell and beta thalassemia.
By Gwendolyn Wu • Nov. 17, 2026 -
Sponsored by SAS
Your AI pilots aren’t stalling because of the AI – they’re stalling because of your environment
As clinical AI adoption accelerates, trust, traceability and readiness matter more than ever.
By Kayt Leonard, Global Director, SAS • Nov. 16, 2026 -
Emerging biotech
One of Europe’s leading VCs banks a €725M ‘crossover’ fund
Sofinnova Partners, which has backed the likes of successful drugmakers such as Abivax, Argenx and Verona Pharma, will use the cash to support a new group of later-stage biotechs.
By Gwendolyn Wu • Nov. 16, 2026 -
News roundup
Novo submits sickle cell drug; Flagship, Gates Foundation deepen ties
Novo views the medicine, acquired in a billion-dollar deal, as a future blockbuster. Meanwhile, a pair of startups forged an RNA editing pact and Astellas lined up two new trials in pancreatic cancer.
By BioPharma Dive staff • Nov. 13, 2026 -
This week in charts
This week in charts: Brain drugs are back on venture capitalists’ minds
Five neurology-focused startups have together raised around $450 million in the last few weeks. Elsewhere, investors had a muted response to the latest cell therapy research.
By Jacob Bell • Nov. 13, 2026 -
IPO window
Windward prices $175M IPO to advance China-licensed lung drugs
The Swiss biotech, which pocketed another $50 million through a concurrent private share sale to Sanofi, is developing a potential competitor to the blockbuster asthma treatment Tezspire.
By Gwendolyn Wu • Nov. 12, 2026 -
News roundup
AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning
The deal gives AstraZeneca a simpler way to make conjugate vaccines. Elsewhere, a psychedelic depression drug was submitted to the FDA and an autoimmune disease-focused biotech’s shares collapsed.
By BioPharma Dive staff • Nov. 11, 2026 -
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
Brain drug revivalLondon biotech Oyster harvests $60M for tau-targeting brain drugs
Oyster says a tweak it's made to traditional protein degrading technology can help break down tau, which has long been a focus of Alzheimer’s drug research.
By Gwendolyn Wu • Nov. 10, 2026 -
China competition
BIO unveils plan for US to remain biotech’s ‘global leader’
A seven-part proposal from the prominent lobbyist lays out a series of initiatives to accelerate drug development in the U.S. and counter China’s fast rise.
By Gwendolyn Wu • Nov. 10, 2026 -
Vir hepatitis D drug succeeds in first pivotal study
A program that’s survived Vir’s pivot away from infectious disease research hit all of its study objectives and appeared more potent than a rival drug also in late-stage development.
By Delilah Alvarado • Nov. 9, 2026 -
Trump administration
Ramaswamy’s biotech baggage haunted his political run
A pivotal Alzheimer’s trial tied to Vivek Ramaswamy’s political rise is a tale of failed endpoints.
By Sy Mukherjee • Nov. 9, 2026 -
News roundup
Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down
The deal is part of a course change for Hims, which had previously sold knockoff GLP-1 drugs. Elsewhere, a medicine Servier recently acquired failed a key trial and Ultragenyx announced staff cuts.
By BioPharma Dive staff • Nov. 6, 2026 -
This week in charts
This week in charts: 3 drug launches Wall Street is watching
The latest installment in BioPharma Dive’s visualization-focused series features a look at investors’ response to a trio of medicines highlighted in quarterly earnings this week.
By Ben Fidler • Nov. 6, 2026 -
Retrieved from Revolution Medicines.
Revolution’s Rasonque off to best cancer drug launch ‘in history’
Wall Street analysts are already resetting projections for Rasonque — but company executives cautioned that it’s too early to draw conclusions about the pancreatic cancer drug’s launch trajectory.
By Kristin Jensen • Nov. 5, 2026 -
Emerging biotech
T-Therapeutics reloads with a $133M megaround for bispecifics
The startup is built around technology it claims can help get after known, but undruggable cancer targets and design particularly selective autoimmune disease treatments.
By Gwendolyn Wu • Nov. 5, 2026 -
Startup launches
Alethio raises $90M to target rare blood cancers
The startup is working on a medicine one of its investors claimed could have a broader reach than other approved drugs for a group of conditions known as myeloproliferative neoplasms.
By Gwendolyn Wu • Nov. 5, 2026 -
Trump administration
Biopharma likely to climb higher after ‘blue wave,’ analysts say
Historical data suggests the sector outperforms after midterm elections. And Democrats, newly in control of Congress, have “bigger fish to fry” than drug pricing, analysts said.
By Jonathan Gardner • Nov. 4, 2026